Similac Superiority Claims Over Enfamil Should Be Modified – NAD
This article was originally published in The Tan Sheet
Executive Summary
Marketing claims that Similac and SimilacAdvance are "'the best' and superior to Enfamil and Enfamil Lipil in terms of a baby's mental development and visual acuity" should be discontinued, the National Advertising Division says in a recent decision
You may also be interested in...
Infant visual acuity
Infants fed formula containing docosahexaenoic acid (DHA) and arachidonic acid (AA) "showed acuity maturation similar to that of the human milk-fed group throughout the first year of life" in a study of 108 healthy term infants published in the August issue of Pediatric Research. The study, by Eileen Birch et al., concludes "early dietary intake of preformed DHA and AA appears necessary for optimal development of the brain and eye of the human infant." The DHA and AA were supplied by Columbia, Md.-based Martek. The company maintains the study "is the first to show a persistent effect in visual acuity development related to dietary intake of DHA." A grant from NIH funded the study while Mead Johnson provided the formula and supplementary funding...
Ross "Improved" Similac infant formula with increased nucleotides now launching.
ROSS PRODUCTS "IMPROVED" SIMILAC INFANT FORMULA LAUNCHING NATIONWIDE in May with increased levels of nucleotides and a new fat blend and protein system, the Columbus, Ohio-based division of Abbott Labs said. Improved Similac infant formula contains 72 mg of nucleotides; "the level of nucleotides in any other infant formula...is less than half the total potentially available nucleotides found in improved Similac and breast milk," Ross stated. The reformulated product is replacing the former version.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC